Open Access Articles- Top Results for Mesoridazine


Systematic (IUPAC) name
10-{2-[(RS)1-Methylpiperidin-2-yl]ethyl}- 2-methylsulfinyl- 10H-phenothiazine
Clinical data
Trade names Serentil
AHFS/ Micromedex Detailed Consumer Information
MedlinePlus a682306
  • US: C (Risk not ruled out)
  • (Prescription only)
oral, intravenous
Pharmacokinetic data
Protein binding 4%
Metabolism Hepatic/Renal
Half-life 24 to 48 hours
Excretion Biliary and renal
5588-33-0 7pxY
PubChem CID 4078
DrugBank DB00933 7pxY
ChemSpider 3936 7pxY
UNII 5XE4NWM740 7pxY
KEGG D02671 7pxY
ChEBI CHEBI:6780 7pxY
Chemical data
Formula C21H26N2OS2
386.576 g/mol
Physical data
Melting point Script error: No such module "convert".
insoluble mg/mL (20 °C)
 14pxY (what is this?)  (verify)

Mesoridazine (Serentil) is a piperidine neuroleptic drug belonging to the class of drugs called phenothiazines, used in the treatment of schizophrenia. It is a metabolite of thioridazine. The drug's name is derived from the methylsulfoxy and piperidine functional groups in its chemical structure.

It has central antiadrenergic, antidopaminergic, antiserotonergic and weak muscarinic anticholinergic effects.

Serious side effects include akathisia, tardive dyskinesia and the potentially fatal neuroleptic malignant syndrome.

Mesoridazine was withdrawn from the United States market in 2004 due to dangerous side effects, namely irregular heart beat and QT-prolongation of the electrocardiogram.[1]

It currently appears to be unavailable worldwide.


  1. ^ [1]

Template:Navbox with collapsible sections

Lua error in package.lua at line 80: module 'Module:Buffer' not found.